Tinea Corporis with Trichophyton Rubrum Mimicking a Flare-Up of Psoriasis UnderTreatment with IL17-Inhibitor Ixekizumab
Open Access
- 1 January 2021
- journal article
- research article
- Published by S. Karger AG in Case Reports in Dermatology
- Vol. 13 (2), 347-351
- https://doi.org/10.1159/000515702
Abstract
Biologics, as IL17 inhibitors, are frequently prescribed for moderate to severe plaque psoriasis. Although mucocutaneous candida infections are a well-known side effect of IL-17 inhibitors, there is no data about dermatophyte infection under this therapy. Generalized tinea corporis can mimic the clinical picture of psoriasis, especially if concomitant treatment with topical corticosteroids is used. Therefore, physician should be aware of this differential diagnosis if they suspect a loss of efficacy of IL-17-inhibitors with a flare-up of psoriasis. (C) 2021 The Author(s). Published by S. Karger AG, BaselThis publication has 12 references indexed in Scilit:
- Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of ExposureDermatology and Therapy, 2020
- Psoriasis Pathogenesis and TreatmentInternational Journal of Molecular Sciences, 2019
- Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3)Journal of the American Academy of Dermatology, 2017
- Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3)British Journal of Dermatology, 2017
- Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III studyBritish Journal of Dermatology, 2017
- Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated dataJournal of the American Academy of Dermatology, 2016
- Perianal Dermatophytosis During Secukinumab Therapy for Plaque PsoriasisJAMA Dermatology, 2016
- Ixekizumab for the Treatment of Psoriasis: A Review of Phase III TrialsDermatology and Therapy, 2016
- Immunity to infection in IL‐17‐deficient mice and humansEuropean Journal of Immunology, 2012
- Unravelling fungal immunity through primary immune deficienciesCurrent Opinion in Microbiology, 2012